Last week, the San Francisco Department of Public Health (SFDPH) confirmed the first case of Avian Influenza-Bird Flu (H5N1) in a child in the city. Coinciding with this alarming development was the Biotech Showcaseâ„¢ conference in San Francisco, where a panel of healthcare experts and biotech industry leaders gathered to discuss strategies to combat the spread of the virus and its consequences.
The discussion began with Emma Wheatley, Executive Director of the Coalition for Epidemic Preparedness Innovations (CEPI), emphasizing the need for a shift in approach towards diagnostics, vaccines, antivirals, and therapeutics in light of the H5N1 outbreak. The panel delved into two key areas of innovation needed to address the virus effectively.
The first area focused on preventing viral transmission through the development of next-generation antivirals. Dr. Jeff Stein, CEO of Cidara Therapeutics, advocated for the creation of long-acting pan-influenza antivirals like CD388, which could provide universal protection against all strains without relying on an immune response.
The second area of innovation centered on understanding and treating the inflammatory immune response triggered by H5N1. Prof. Niels C. Riedemann, CEO of InflaRx N.V., highlighted the importance of developing therapeutics to address the harmful effects of the virus on the body, particularly in severe cases.
One major concern discussed was the potential for a cytokine storm, where the body releases excessive pro-inflammatory cytokines, leading to severe complications like pulmonary edema and organ failure. Dr. Phillip Chan, CEO of CytoSorbents Corporation, proposed using blood purification with CytoSorb® to manage deadly inflammation and improve outcomes for severely ill patients.
The panelists agreed that the focus should be on reducing the spread of H5N1 and mitigating the impacts of post-infection inflammation. The urgent need for innovative solutions to combat the virus and protect public health was a central theme of the discussion. As we navigate this new threat, it is crucial that we prioritize research and development efforts to stay ahead of potential outbreaks and safeguard the well-being of our communities.
